Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Summary

The purpose of the AveNEC trial is to investigate the clinical activity and safety of avelumab in patients with NEC G3 (WHO 2010), including "NET G3" who are progressive after first line chemotherapy.

Timeline

Start

2017-12-07

Primary completion

2022-02-18

Completion

2022-02-18

Publications

• Mohrmann L, Rostock L, Werner M, Oles M, Arnold JS, Paramasivam N, Johrens K, Rupp L, Schmitz M, Richter D, Uhrig S, Frohlich M, Hutter B, Hullein J, Jahn A, Arlt M, Mohrmann EE, Hanf D, Gieldon L, Kreutzfeldt S, Heilig CE, Teleanu MV, Lipka DB, Beck K, Baude-Muller A, Mock A, Jelas I, Rieke DT, Wiesweg M, Brandts C, Boerries M, Illert AL, Desuki A, Kindler T, Krackhardt AM, Westphalen CB, Christopoulos P, Apostolidis L, Stenzinger A, Allgauer M, Neumann O, Kerle IA, Horak P, Heining C, Grosch H, Schrock E, Hubschmann D, Frohling S, Glimm H. Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. Med. 2025 Jun 13;6(6):100612. doi: 10.1016/j.medj.2025.100612. Epub 2025 Mar 18.

Drugs

Indications